Spinosin Attenuates Alzheimer's Disease-Associated Synaptic Dysfunction via Regulation of Plasmin Activity |
Cai, Mudan
(Department of Life and Nanopharmaceutical Science, Kyung Hee University)
Jung, Inho (Department of Life and Nanopharmaceutical Science, Kyung Hee University) Kwon, Huiyoung (Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University) Cho, Eunbi (Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University) Jeon, Jieun (Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University) Yun, Jeanho (Department of Biochemistry, College of Medicine, Dong-A University) Lee, Young Choon (Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University) Kim, Dong Hyun (Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University) Ryu, Jong Hoon (Department of Life and Nanopharmaceutical Science, Kyung Hee University) |
1 | Barker, R., Love, S. and Kehoe, P. G. (2010) Plasminogen and plasmin in Alzheimer's disease. Brain Res. 1355, 7-15. DOI |
2 | Castello, N. A., Nguyen, M. H., Tran, J. D., Cheng, D., Green, K. N. and LaFerla, F. M. (2014) 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS ONE 9, e91453. DOI |
3 | Criscuolo, C., Fabiani, C., Bonadonna, C., Origlia, N. and Domenici, L. (2015) BDNF prevents amyloid-dependent impairment of LTP in the entorhinal cortex by attenuating p38 MAPK phosphorylation. Neurobiol. Aging 36, 1303-1309. DOI |
4 | de Pins, B., Cifuentes-Diaz, C., Farah, A. T., Lopez-Molina, L., Montalban, E., Sancho-Balsells, A., Lopez, A., Gines, S., Delgado-Garcia, J. M., Alberch, J., Gruart, A., Girault, J. A. and Giralt, A. (2019) Conditional BDNF delivery from astrocytes rescues memory deficits, spine density, and synaptic properties in the 5xFAD mouse model of Alzheimer disease. J. Neurosci. 39, 2441-2458. |
5 | Dotti, C. G., Galvan, C. and Ledesma, M. D. (2004) Plasmin deficiency in Alzheimer's disease brains: causal or casual? Neurodegener. Dis. 1, 205-212. DOI |
6 | Draxler, D. F., Sashindranath, M. and Medcalf, R. L. (2017) Plasmin: a modulator of immune function. Semin. Thromb. Hemost. 43, 143-153. DOI |
7 | ElAli, A., Bordeleau, M., Theriault, P., Filali, M., Lampron, A. and Rivest, S. (2016) Tissue-plasminogen activator attenuates Alzheimer's disease-related pathology development in APPswe/PS1 mice. Neuropsychopharmacology 41, 1297-1307. DOI |
8 | Gao, L., Tian, M., Zhao, H. Y., Xu, Q. Q., Huang, Y. M., Si, Q. C., Tian, Q., Wu, Q. M., Hu, X. M., Sun, L. B., McClintock, S. M. and Zeng, Y. (2016) TrkB activation by 7, 8-dihydroxyflavone increases synapse AMPA subunits and ameliorates spatial memory deficits in a mouse model of Alzheimer's disease. J. Neurochem. 136, 620-636. DOI |
9 | Ittner, L. M. and Gotz, J. (2011) Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12, 65-72. |
10 | Gray, K. and Ellis, V. (2008) Activation of pro-BDNF by the pericellular serine protease plasmin. FEBS Lett. 582, 907-910. DOI |
11 | Guntupalli, S., Widagdo, J. and Anggono, V. (2016) Amyloid--induced dysregulation of AMPA receptor trafficking. Neural Plast. 2016, 3204519. |
12 | Jacobsen, J. S., Comery, T. A., Martone, R. L., Elokdah, H., Crandall, D. L., Oganesian, A., Aschmies, S., Kirksey, Y., Gonzales, C., Xu, J., Zhou, H., Atchison, K., Wagner, E., Zaleska, M. M., Das, I., Arias, R. L., Bard, J., Riddell, D., Gardell, S. J., Abou-Gharbia, M., Robichaud, A., Magolda, R., Vlasuk, G. P., Bjornsson, T., Reinhart, P. H. and Pangalos, M. N. (2008) Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc. Natl. Acad. Sci. U.S.A. 105, 8754-8759. DOI |
13 | Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D. and Selkoe, D. J. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 5819-5824. DOI |
14 | Lee, H. K., Takamiya, K., Han, J. S., Man, H., Kim, C. H., Rumbaugh, G., Yu, S., Ding, L., He, C., Petralia, R. S., Wenthold, R. J., Gallagher, M. and Huganir, R. L. (2003) Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 112, 631-643. DOI |
15 | Ko, S. Y., Lee, H. E., Park, S. J., Jeon, S. J., Kim, B., Gao, Q., Jang, D. S. and Ryu, J. H. (2015) Spinosin, a C-glucosylflavone, from Zizyphus jujuba var. spinosa ameliorates Abeta1-42 oligomer-induced memory impairment in mice. Biomol. Ther. (Seoul) 23, 156-164. DOI |
16 | Krueger, S. R., Ghisu, G. P., Cinelli, P., Gschwend, T. P., Osterwalder, T., Wolfer, D. P. and Sonderegger, P. (1997) Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J. Neurosci. 17, 8984-8996. DOI |
17 | Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., Jackson, G. R. and Kayed, R. (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2, 700. DOI |
18 | Lebeurrier, N., Liot, G., Lopez-Atalaya, J. P., Orset, C., Fernandez-Monreal, M., Sonderegger, P., Ali, C. and Vivien, D. (2005) The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol. Cell. Neurosci. 30, 552-558. DOI |
19 | Ledesma, M. D., Da Silva, J. S., Crassaerts, K., Delacourte, A., De Strooper, B. and Dotti, C. G. (2000) Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 1, 530-535. DOI |
20 | Li, W. Y., Chong, S. S., Huang, E. Y. and Tuan, T. L. (2003) Plasminogen activator/plasmin system: a major player in wound healing? Wound Repair Regen. 11, 239-247. DOI |
21 | Sappino, A. P., Madani, R., Huarte, J., Belin, D., Kiss, J. Z., Wohlwend, A. and Vassalli, J. D. (1993) Extracellular proteolysis in the adult murine brain. J. Clin. Invest. 92, 679-685. DOI |
22 | Maren, S. and Baudry, M. (1995) Properties and mechanisms of long-term synaptic plasticity in the mammalian brain: relationships to learning and memory. Neurobiol. Learn. Mem. 63, 1-18. DOI |
23 | Ono, K., Condron, M. M. and Teplow, D. B. (2009) Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc. Natl. Acad. Sci. U.S.A. 106, 14745-14750. DOI |
24 | Parameshwaran, K., Dhanasekaran, M. and Suppiramaniam, V. (2008) Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp. Neurol. 210, 7-13. DOI |
25 | Park, H. J., Jung, I. H., Kwon, H., Yu, J., Jo, E., Kim, H., Park, S. J., Lee, Y. C., Kim, D. H. and Ryu, J. H. (2019) The ethanol extract of Zizyphus jujuba var. spinosa seeds ameliorates the memory deficits in Alzheimer's disease model mice. J. Ethnopharmacol. 233, 73-79. DOI |
26 | Rodier, M., Prigent-Tessier, A., Bejot, Y., Jacquin, A., Mossiat, C., Marie, C. and Garnier, P. (2014) Exogenous t-PA administration increases hippocampal mature BDNF levels. plasmin- or NMDAdependent mechanism? PLoS ONE 9, e92416. DOI |
27 | Schaller, J. and Gerber, S. S. (2011) The plasmin-antiplasmin system: structural and functional aspects. Cell. Mol. Life Sci. 68, 785-801. DOI |
28 | Sengupta, U., Nilson, A. N. and Kayed, R. (2016) The role of amyloid- oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6, 42-49. DOI |
29 | Shergis, J. L., Ni, X., Sarris, J., Zhang, A. L., Guo, X., Xue, C. C., Lu, C. and Hugel, H. (2017) Ziziphus spinosa seeds for insomnia: a review of chemistry and psychopharmacology. Phytomedicine 34, 38-43. DOI |
30 | Sevush, S. and Leve, N. (1993) Denial of memory deficit in Alzheimer's disease. Am. J. Psychiatry 150, 748-751. DOI |
31 | Sutton, M. A. and Schuman, E. M. (2006) Dendritic protein synthesis, synaptic plasticity, and memory. Cell 127, 49-58. DOI |
32 | Tucker, H. M., Kihiko-Ehmann, M., Wright, S., Rydel, R. E. and Estus, S. (2000) Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J. Neurochem. 75, 2172-2177. DOI |
33 | Arancibia, S., Silhol, M., Mouliere, F., Meffre, J., Hollinger, I., Maurice, T. and Tapia-Arancibia, L. (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol. Dis. 31, 316-326. DOI |
34 | Van Nostrand, W. E. and Porter, M. (1999) Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38, 11570-11576. DOI |
35 | Vassalli, J. D., Sappino, A. P. and Belin, D. (1991) The plasminogen activator/plasmin system. J. Clin. Invest. 88, 1067-1072. DOI |
36 | Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J. and Selkoe, D. J. (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552-557. DOI |
37 | Alkjaersig, N., Fletcher, A. P. and Sherry, S. (1959) The mechanism of clot dissolution by plasmin. J. Clin. Invest. 38, 1086-1095. DOI |
38 | Angelucci, F., Cechova, K., Prusa, R. and Hort, J. (2019) Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. CNS Neurosci. Ther. 25, 303-313. DOI |
39 | Backman, L., Small, B. J. and Fratiglioni, L. (2001) Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain 124, 96-102. DOI |
40 | Baranello, R. J., Bharani, K. L., Padmaraju, V., Chopra, N., Lahiri, D. K., Greig, N. H., Pappolla, M. A. and Sambamurti, K. (2015) Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr. Alzheimer Res. 12, 32-46. DOI |